AusCann inks deal with Jade Cannabis and appoints Master Grower

Company News

by Anna Napoli

Leading medical cannabis company AusCann (ASX:AC8) has entered into a research agreement with Canadian group Jade Cannabis.

AusCann has engaged Jade Cannabis to undertake research and development work at its Canadian facility for an initial three-year period.

 The company says the aim of the research is to obtain greater yield per square metre of grow room, resulting in more cost-effective cannabis pharmaceuticals for patients

Meantime, the company has appointed Canadian Luke Pigeau as its new Master Grower.

He was selected after an extensive global search and will oversee AusCann’s cultivation activities, accelerating AusCann’s Australian medical cannabis manufacturing operation.

Shares in AusCann (ASX:AC8) closed flat at $1.26 on Friday.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.